The Efficacy and Safety of B-Cell Maturation Antigen (BCMA) Antibody-Drug Conjugates (ADC) in Development against Cancer: A Systematic Review
BCMA-targeted ADC candidates show encouraging efficacy in RRMM, particularly belantamab mafodotin. However, frequent AEs, especially ocular and hematologic toxicities, underscore the need for optimization in ADC design. Further research should prioritize enhancing safety while maintaining clinical benefit.
Authors
- Catherine E. King (ORCID: https://orcid.org/0000-0002-5761-4746)
- Veysel Kayser (ORCID: https://orcid.org/0000-0003-1310-9534)
- Harunor Rashid (ORCID: https://orcid.org/0000-0003-2286-5139)
- Jing Shan (ORCID: https://orcid.org/0000-0002-7750-3824)
Institutions
- The University of Sydney (AU)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-12-01
- DOI
- https://doi.org/10.32604/or.2025.070851
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00